---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-007059"
form_type: "8-K"
ticker: "FLGT"
cik: "0001674930"
company_name: "Fulgent Genetics, Inc."
filed_at: "2022-05-03T23:59:59+00:00"
generated_at: "2026-06-26T01:33:01.987168+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Fulgent Genetics Q1 revenue $320.3M, core revenue up 59%, raises FY outlook to $660M

## Summary
- Revenue $320.3M (down from $359.4M Q1 2021); GAAP net income $154M ($4.93/share).
- Core revenue ex-COVID NGS $25.1M (+59% YoY); billable tests ~3.2M vs 3.8M.
- Non-GAAP net income $158.7M ($5.08/share); Adjusted EBITDA $213.5M.
- Raises FY 2022 revenue outlook to $660M from $600M; core revenue outlook to $180M from $175M.
- Cash & investments $1.1B at March 31; closed $170M acquisition of Inform Diagnostics on April 26.

## SEC filing metadata
- accession: 0000950170-22-007059
- form_type: 8-K
- ticker: FLGT
- cik: 0001674930
- company_name: Fulgent Genetics, Inc.
- filed_at: 2022-05-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674930/000095017022007059/0000950170-22-007059-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674930/000095017022007059/flgt-20220503.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-007059
- JSON: https://secwatch.observer/filing/0000950170-22-007059.json
- Plain text: https://secwatch.observer/filing/0000950170-22-007059.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.